Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7286165 | 1.00 | DPP4 (0.68) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL1980156 | 1.00 | DPP4 (0.68) | DPP4F2ADRA2AADRA2CLMNA | |
| Hydrochloric Acid SCHEMBL22713306 | 0.97 | DPP4 (0.65) | DPP4F2ADRA2AADRA2CLMNA | |
| Hydrochloric Acid SCHEMBL3753145 | 0.97 | DPP4 (0.65) | DPP4F2ADRA2AADRA2CLMNA | |
| Bromide SCHEMBL11538603 | 0.97 | DPP4 (0.65) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL3271282 | 0.85 | DPP4 (0.45) | DPP4ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL20634768 | 0.84 | DPP4 (0.62) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL77070 | 0.83 | DPP4 (0.68) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL10506371 | 0.83 | DPP4 (0.68) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL3367415 | 0.83 | DPP4 (0.68) | DPP4F2ADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119898789-A | Flower-like sphere mordenite as well as preparation method and application thereof | 中国石油化工股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-105939736-B | Odor masking amine compositions | 阿肯马法国公司 | 2020-11-06 | — | — | CN | claimed |
| CN-108250115-B | The method of father's younger male cousin's amine coupling synthesizing aryl thioether | 成都理工大学 | 2019-11-08 | — | — | CN | claimed |
| EP-3102249-B1 | ODOUR-MASKED AMINE COMPOSITION | ARKEMA FRANCE (FR) | 2019-10-16 | — | — | EP | claimed |
| US-10315982-B2 | Odour-masked amine composition | ARKEMA FRANCE (FR) | 2019-06-11 | — | — | US | claimed |
| US-20160340292-A1 | ODOUR-MASKED AMINE COMPOSITION | ARKEMA FRANCE (FR) | 2016-11-24 | — | — | US | claimed |
| WO-2014001075-A1 | PROCESS FOR RACEMIZING OPTICALLY ACTIVE ARYLALKYLAMINES | BASF SE (DE) | 2014-01-03 | — | — | WO | claimed |
| US-20130345475-A1 | PROCESS FOR THE RACEMIZATION OF OPTICALLY ACTIVE ARYLALKYLAMINES | BASF SE (DE) | 2013-12-26 | — | — | US | claimed |
| WO-2012037258-A1 | PROCESSES FOR PREPARING 1,2-SUBSTITUTED CYCLOPROPYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | WO | claimed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | claimed |
| EP-2032587-A2 | ROSUVASTATIN INTERMEDIATES AND PROCESS FOR THE PREPARATION OF ROSUVASTATIN | Teva Pharmaceutical Industries Ltd. (IL) | 2009-03-11 | — | — | EP | claimed |
| WO-2008130678-A2 | ROSUVASTATIN INTERMEDIATES AND PROCESS FOR THE PREPARATION OF ROSUVASTATIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-30 | — | — | WO | claimed |
| CN-1225452-C | Prepn. of (+)-trans-chrysanthemic acid | SUMITOMO CHEMICAL CO (JP) | 2005-11-02 | — | — | CN | claimed |
| US-6310207-B1 | MANNICH REACTION | CHONG KUN DANG CORP. (KR) | 2001-10-30 | — | — | US | claimed |
| CN-1298862-A | Prepn. of (+)-trans-chrysanthemic acid | SUMITOMO CHEMICAL CO (JP) | 2001-06-13 | — | — | CN | claimed |
| WO-1999002530-A1 | A PROCESS OF MANUFACTURING CAMPTOTHECIN DERIVATIVES | CHONG KUN DANG CORP. (KR) | 1999-01-21 | — | — | WO | claimed |
| WO-1996002492-A1 | METHOD OF MAKING A BENZYLPROPANAMINE | NSP PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | claimed |
| EP-0508307-B1 | Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound | SUMITOMO CHEMICAL CO (JP) | 1995-11-29 | — | — | EP | claimed |
| EP-0508307-A2 | Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-10-14 | — | — | EP | claimed |
| US-4410730-A | Process for the production of o-(N-monosubstituted amino)benzyl alcohols | SHIONOGI & CO., LTD. (JP) | 1983-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345475-A1 | PROCESS FOR THE RACEMIZATION OF OPTICALLY ACTIVE ARYLALKYLAMINES | HRH1, HNMT, HRH3 | DPP4 2210/4885F2 3100/4885ADRA2A 417/4885 |
| US-20160340292-A1 | ODOUR-MASKED AMINE COMPOSITION | OR51E2, OR10J3, PNMT | DPP4 3909/4885F2 3482/4885ADRA2A 140/4885 |
| US-10315982-B2 | Odour-masked amine composition | OR51E2, OR10J3, CHRM1 | DPP4 4000/4885F2 2850/4885ADRA2A 144/4885 |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | DPP4 924/4885F2 4840/4885ADRA2A 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.